cardio update europe 2020
TRANSCRIPT
6th European Update Congress in CardiologyVirtual, 2 – 3 October 2020
Cardio Update Europe 2020
Scientific BoardMichael Böhm, GermanyKurt Huber, AustriaAndre Keren, Israel
www.cardio-update-europe.eu
KI2
0167
_car
dio
_A5_
land
scap
e
karger.com/cardiovascularsystem
CardiovascularSystem
Scientific Board
Michael Böhm (Germany)
Kurt Huber (Austria)
Andre Keren (Israel)
Dear Colleagues,Welcome to the 6th Cardio Update Europe a completely virtual event this year!
We have been providing top-notch, high-quality educational meetings for cardiologists and heart speci-alists to learn, interact and exchange with each other for half a decade.
Again this year, you can expect a proven concept where clinicians, as well as practitioners, will receive a comprehensive, cutting-edge update of recent developments in the field.
Leading European specialists will provide you with critical analyses of latest research, as well as recom-mendations for your daily practice, along with many interaction opportunities …all unbiased and not influenced by industry.
Take the opportunity to join open discussions during the lectures with the panel via livechat – send in your pressing questions!
And don’t forget to attend the always interesting symposia on both days: Clinical Strategies in Heart Failure: Optimizing RAASi use in patients with hyperkalaemia and improving outcomes in patients with iron deficiency and A Pivotal Moment for Renal Denervation.
Last, but not least, thank you to our Partners: Daiichi Sankyo, Vifor Pharma, Medtronic, Servier and Boehringer Ingelheim/Lilly Diabetes Alliance. We couldn‘t do it without you!
Sincerely,
Michael Böhm Kurt Huber Andre Keren
KI2
0167
_car
dio
_A5_
land
scap
e
karger.com/cardiovascularsystem
CardiovascularSystem
Friday October 2, 2020
Welcome 9:50
Prevention - Targets and Clinical ResultsDavid Wood, Ireland
• European guidelines on CVD prevention• Hypertension• Lipids• Diabetes• Preventive Cardiology
10:00
Hot Topic: Sports CardiologySanjay Sharma, UK
• Pre-participation Cardiac Screening in Athletes• The Black Athlete’s Heart: Revisited• Differentiating Cardiac Physiology From Cardiomyopathy• Hypertrophic Cardiomyopathy and Competitive Sport
10:45
Break 11:30
160140
120
300
100
280
80 260
60
240
40
220
20
200
0
180
mmHg
HypertensionFelix Mahfoud, Germany
• Epidemiology• Hypertension Management• Device-based Hypertension Therapy
12:00
Industry-sponsored Symposium 12:45
Break 13:30
Cardiomyopathy / MyocarditisAndre Keren, Israel
• Myocarditis vs myocardial damage in COVID 19 infection• Myocarditis – Role of repeat CMR• Viral presence and persistence• ARVC with LV Phenotype: Dd from DCM• Risk scores for SCD • Disease changing therapy: Mavacamten in NHCM and in HOCM• The MAVERICK-HCM study• Mavacamten in HOCM
14:30
Heart FailureMichael Böhm, Germany
• Time is heart?• News on therapy• New Studies• Guideline Recomendations
15:15
Break 16:00
Hot Topic: Infectious Diseases and the HeartFriedrich Thienemann, Switzerland
• Spectrum of infectious diseases affecting the heart• Interaction infectious diseases & cardiovascular disease• HIV - examples of infectious diseases affecting the
entire axis of the heart
16:30
Valvular Heart Disease & Congenital DefectsHelmut Baumgartner, Germany
• Aortic valve• Mitral valve• Tricuspid valve• Congenital defects
17:15
Program
Saturday, 3 October
Coronary Interventions & Anti-Thrombotic StrategiesKurt Huber, Austria
• Coronary Intervention• Myocardial Revascularization• Interventional Techniques• Antithrombotic Strategies
9:30
Atrial Fibrillation & Stroke PreventionJohn Camm, UK
• Anticoagulation for NVAF patients who are old and frail• Anticoagulation for NVAF in patients with renal impairment• Anticoagulation for NVAF in patients with diabetes• Adherence, persistence and dosing for anticoagulation
of NVAF patients• Left atrial appendage occlusion as an alternative to
anticoagulation for NVAF
10:15
Break 11:00
Acute Cardiac CareAlexandre Mebazaa, France
• Contemporay treatment of acute heart failure• Novelties in cardiogenic shock• Post-discharge management in acute cardiac care
11:15
Industry-sponsored Symposium 12:00
Break 12:45
ImagingUdo Sechtem, Germany
• Cardiac MRI (CMR) - Covid-19 - Minoca• Cardiac CT - CT CAC screening - Testing Strategies for stable CAD
13:45
Ventricular ArrhythmiasJosef Kautzner, Czech Republic
• Fighten sudden cardiac death• Non-pharmacological treatment of VAs
14:30
End of Congress 15:15
The Cardio Update Europe 2020 has been accredited by the European
Accreditation Council for Continuing Medical Education (EACCME®)
for a maximum of 9 European CME credits (ECMEC®s)
Speakers
Prof. David WoodNational Institute for Prevention and Cardiovascular Health, National University of Ireland – Galway
University Road, H91 TK33 Galway (Ireland) [email protected]
Prof. Sanjay SharmaHeart of Sports
54 Micheldever Road, SE12 8LU London (UK) [email protected]
Prof. Felix MahfoudUniversity Hospital of Saarland Department of Internal Medicine III Cardiology, Angiology and Intensive Care
Kirrberger Strasse, 66421 Homburg/Saar (Germany) [email protected]
Prof. Andre KerenAssuta Hashalom Heart Institute (Tel Aviv) Hadassah Hebrew University (Jersusalem) Heart Failure and Heart Muscle Diseases Center
Kiryat Hadassah, POB 12000 Jerusalem (Israel) [email protected]
Prof. Michael BöhmUniversity Hospital of Saarland Department of Internal Medicine III Cardiology, Angiology and Intensive Care
Kirrberger Strasse, 66421 Homburg/Saar (Germany) [email protected]
Prof. Friedrich ThienemannDepartment of Medicine, Cape Heart Institute, University of Cape Town, South Africa. Department of Internal Medicine,University Hospital Zurich, Switzerland. [email protected]
Prof. Helmut BaumgartnerUniversity Hospital Münster Dept. of Cardiology III: Adult Congenital and Valvular Heart DiseaseAlbert-Schweitzer Campus 1, 48149 Muenster (Germany) [email protected]
Prof. Kurt HuberWilhelminen Hospital 3. Medical Department Cardiology & Intensive Care Medicine
Montleartstrasse 37, 1160 Vienna (Austria) [email protected]
Prof. John CammSt. George‘s University Cardiology Clinical Academic Group Molecular & Clinical Sciences Institute
London, SW17 0RE (UK) [email protected]
Prof. Alexandre MebazaaLariboisiere Hospital Department of Anesthesia-Resuscitation
2 rue Ambroise Paré, 75475 Paris (France) [email protected]
Prof. Udo SechtemRobert Koch Krankenhaus Department of Cardiology and Cardiologicum
Stuttgart (Germany) [email protected]
Prof. Josef KautznerInstitute for Clinical and Experimental Medicine, Prague
Prague (Czech Republic) [email protected]
View the Cardio Update Europe lectures on-demand, whereever and whenever you want – free for delegates!
How it works:
• Register at www.streamed-up.com for free
• From the left-hand menu, choose European Update Congresses
• Find the video that you want to see and enter the code: CardioEurope20 in the shopping cart (code is only accessible to 2020 delegates, 4 – 6 weeks after the event)
learning can be this easy…
ADV Booklet Congresso_210x148.indd 1ADV Booklet Congresso_210x148.indd 1 29/07/20 14:4029/07/20 14:40
100 million patientstreated each day worldwide withServier medicines
GB
E/St
udio
- P
hoto
san
jeri©
iSto
ckG
etty
Imag
es P
lus
- 20
IN 2
116
IA
Servier, an independent pharmaceutical company with 22,000 employees in 66 countries committed to therapeutic progress to serve patient needs.
servier.com
Optimising RAASi use in patients with hyperkalaemia and improving outcomes in patients with iron deficiencyChair: Prof. Andre Keren (Israel)
CLINICAL STRATEGIES IN HEART FAILURE:
Sponsored by
Cardio Update Europe 2020Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organiser to hold the symposium.
© 2020 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved.Date of preparation: September 2020. HQ-FCM-2000095
Implementing new approaches in hyperkalaemia management: a tool for RAASi therapy optimisationProf. Antoni Bayés-Genís (Spain)
Iron deficiency management in clinical practice: what is an effective strategy to improve patient outcomes?Prof. Kurt Huber (Austria)
Friday 2 October 2020, 12.45–13.30 CET
VIF1039 Cardio update Ad (A5).indd 1VIF1039 Cardio update Ad (A5).indd 1 24/09/2020 12:5424/09/2020 12:54
Date of preparation: July 2019 © 2019 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved.
HQ-RAY-1900019
Advancing hyperkalaemia and SHPT management in CKD
Friday, September 20, 2019; 16:45 - 17:45
Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on the choice of topic and content. Payment has been made to the congress organizer to hold the symposium.
NEPHRO UPDATE EUROPE 2019
National House of Vinohrady, Prague, Czech Republic
● Optimizing RAASi therapy in ND-CKD patients through hyperkalaemia management
Speaker: Prof. Hermann Haller, Germany
● Current concepts for the management of SHPT in ND-CKD patients
Speaker: Prof. David Goldsmith, UK
A PARTNER OF CHOICEFOR PHARMACEUTICALS AND INNOVATIVE PATIENT-FOCUSED SOLUTIONS
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care.
Vifor Pharma Group holds a central position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.
viforpharma.com
COMPANYPROFILE
VIF1039 Cardio update Ad (A5).indd 2VIF1039 Cardio update Ad (A5).indd 2 24/09/2020 12:5424/09/2020 12:54
Date of preparation: July 2019 © 2019 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved.
HQ-RAY-1900019
Advancing hyperkalaemia and SHPT management in CKD
Friday, September 20, 2019; 16:45 - 17:45
Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on the choice of topic and content. Payment has been made to the congress organizer to hold the symposium.
NEPHRO UPDATE EUROPE 2019
National House of Vinohrady, Prague, Czech Republic
● Optimizing RAASi therapy in ND-CKD patients through hyperkalaemia management
Speaker: Prof. Hermann Haller, Germany
● Current concepts for the management of SHPT in ND-CKD patients
Speaker: Prof. David Goldsmith, UK
A PARTNER OF CHOICEFOR PHARMACEUTICALS AND INNOVATIVE PATIENT-FOCUSED SOLUTIONS
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care.
Vifor Pharma Group holds a central position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.
viforpharma.com
COMPANYPROFILE
VIF1039 Cardio update Ad (A5).indd 2VIF1039 Cardio update Ad (A5).indd 2 24/09/2020 12:5424/09/2020 12:54
NEW DATAMORE MOMENTUMThe Medtronic Renal Denervation (RDN) systemis proven to reduce blood pressure †
Data from the SPYRAL OFF MED Pivotal Trial1
For more details, visit RenalDenervation.com
† At three months
†† ANCOVA Adjusted
1. Böhm M, Kario K, Townsend R, et al. Catheter-based Renal Denervation in the Absence of Antihypertensive Medications: Primary Results from the SPYRAL HTN-OFF MED Pivotal Trial. The Lancet 2020; in press.
RDN REDUCES BLOOD PRESSURE 24 HOURS A DAY, INCLUDING DURING HIGH RISK TIME
24-h
r SB
P (m
mH
g)
RDN Baseline RDN 3-months Diff erence
130
155
150
160
140
135
12am 4am2am 8am6am 12pm10am 2pm 4pm 6pm 8pm 10pm
High Risk Zone
24-h
r SB
P (m
mH
g)
Sham Baseline Sham 3-months Diff erence
130
155
150
160
140
135
12am 4am2am 8am6am 12pm10am 2pm 4pm 6pm 8pm 10pm
High Risk Zone
BLOOD PRESSURE CHANGE (mmHg) BASELINE TO 3 MONTHSRenal denervation with the Symplicity Spyral™ Multi-Electrode RDN Catheter lowered BP in the SPYRAL OFF MED Pivotal clinical trial.
ZERO device- or procedure-related adverse events through three months in the RDN treatment arm
SUPERIOR BP REDUCTIONS compared to sham at 3 months in the absence of anti-HTN meds*
* An analysis of covariance model was used adjusting for baseline blood pressure
Δ -6.6 mmHg. p<0.001††
Offi ce SBP
-2.5
-9.2
RDN Sham
Baseline: 163n=156
Baseline: 163n=150
Δ -4.0 mmHg. p<0.001††
24-Hour SBP
-4.7
-0.6RDN Sham
Baseline: 151n=140
Baseline: 151n=134
For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in France.
UC202012078bEE © Medtronic 2020. All rights reserved.
UC202012078bEE RDN Pivotal Results A5 cor2.indd 1 04/08/2020 09:13
SAVE THE DATE!Cardio Update Europe 20212 – 3 July, Prague, Czech Republic
To stay updated follow us on twitter @medupdateeurope
or visit our website: www.medupdate-europe.eu
Congress Hostmed update europe GmbHHagenauer Straße 53, D-65203 Wiesbaden, GermanyPhone: +49(0)611 9458799-0 Fax: +49(0)611 [email protected] www.medupdate-europe.eu
Registration includes:
• Participation in all lectures and the interactive case discussion
• Seminar compendium to download
• Free access to a selection of lectures as video-on-demand on www.streamed-up.com
Congress Organisationwikonect GmbHHagenauer Straße 53, D-65203 Wiesbaden, GermanyPhone: +49(0)611 949154-18, Fax: +49(0)611 [email protected], www.wikonect.de
Useful Information
The following companies disclose their support in accordance with the FSA Code or with internal transparency rules: Daiichi Sankyo, Vifor Pharma, Medtronic, Servier and Boehringer Ingelheim/Lilly Diabetes Alliance. The support entitles companies to a mention on the printed materials and an exhibition stand at the event. For more details see www.cardio-update-europe.eu. The sponsoring companies have no influence on the content or program of the meeting.